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Scenario 2: a financial break-even analysis in which the threshold local TMP-SMX-E.coli resistance was explored by keeping the resistance rate for Cipro XR constant at 1.0%. Scenario 3: a telephone treatment protocol scenario in which an initial office visit and an initial urinalysis were averted since prescribing was carried out by telephone.
Scenario 4: a treatment scenario using data reported on the average duration of therapy for each antibiotic used to treat uncomplicated UTI.
Scenario 5: a worst-case scenario for ciprofloxacin resistance (10%).
The model was based on the following assumptions. The initial office visit included only an in-office urinalysis, but no culture or sensitivity testing. Both treatment options were delivered for 3 days, and after this period infections were either cured or persistent. Persistent infections were assumed to necessitate a second visit, either to the physician or to an emergency room (ER). The second visit was assumed to include a second urinalysis, an initial urine culture and laboratory sensitivity test, and a successful 7-day treatment with a different antibiotic. The time horizon was unclear.
Outcomes assessed in the review
Although the input parameters of the model were not reported explicitly, it appears that the following parameters were used: the rate of local antibiotic resistance, the rates of clinical failure and success after initial treatment, the percentage of failures that result in an ER visit for treatment, the percentage of failures that result in a second physician's office visit, the rates of success after the ER visit and second office visit.
Study designs and other criteria for inclusion in the review
The authors did not report the study designs eligible for inclusion in the review. They do not seem to have used strict inclusion criteria pertaining to study design.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
The authors did not state any methods used to judge the relevance and validity of the data.
Number of primary studies included
Although not explicitly reported, it seems that five primary studies were included as sources of effectiveness evidence.
Methods of combining primary studies
The authors do not appear to have combined the results of the individual studies. 
Investigation of differences between primary studies
No differences between the primary studies were investigated.
Results of the review
The success rate after an initial office visit was 92.35% with TMP-SMX and 99.5% with Cipro XR.
The failure rate among TMP-SMX-resistant patients treated with TMP-SMX was 50%.
Among those who failed first-line therapy, the success rate after a second office visit was 7.04% with TMP-SMX and 0.45% with Cipro XR.
Among those who failed first-line therapy, the success rate after an ER visit was 0.61% with TMP-SMX and 0.04% with Cipro XR.
In the 1a scenario, the average TMP-SMX and ciprofloxacin E. coli resistance rates for uncomplicated UTI isolates were 15.31% and 1.03%, respectively.
In the 1b scenario, the average TMP-SMX and ciprofloxacin E. coli resistance rates for UTI were 16.1% and 2.5%, respectively.
Methods used to derive estimates of effectiveness
The authors made assumptions, based on the available medical literature, about some measures of effectiveness.
Estimates of effectiveness and key assumptions
The failure rate of Cipro XR was assumed to equal that of TMP-SMX administered to TMP-SMX-resistant patients (50%).
All TMP-SMX-susceptible infections and ciprofloxacin-susceptible infections were assumed to be cured when treated with TMP-SMX and ciprofloxacin, respectively.
At the initial stage of therapy, patients were assumed not to visit ERs.
The percentage of failures that resulted in an ER visit was 8%, while the percentage of failures that resulted in a second physician's office visit was 92%.
Measure of benefits used in the economic analysis
The authors did not derive a summary measure of benefit in the economic analysis. The study was therefore characterised as a cost-consequences analysis.
Direct costs
From the perspective of the MCO, the direct medical costs included in the analysis were for the drugs (generic TMP-SMX and Cipro XR at the described doses), the physician's fee for an office visit, the physician's fee for processing a urinalysis; laboratory fees for a urinalysis, laboratory fees for culture and sensitivity test, emergency department visit, emergency department laboratory fees for culture and sensitivity test, and second antibiotic treatment administered for 7 days after failure of initial treatment.
The unit costs were explicitly described. All the costs were derived from reimbursement amounts provided by a major employee health and benefit plan provider, based in the mid-Atlantic region of the USA. The model also incorporated co-payments for office visits, for a generic TMP-SMX prescription, and for a brand-name prescription. The second drug was assumed to be a branded product at equal per-dose cost to Cipro XR and prescribed once daily for 7 days. All the quantities of resources used were derived from the model. The price year was not reported. Discounting was not relevant as the costs were incurred during a short time (less than 2 years).
Statistical analysis of costs
The costs were treated deterministically. Therefore, no statistical analysis of the costs was undertaken.
Indirect Costs
The indirect costs were not included in the analysis.
Currency
US dollars ($).
Sensitivity analysis
No sensitivity analysis was carried out.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The total costs were reported per patient.
In scenario 1a, the average total treatment cost was $59.40 with TMP-SMX (resistance rate 15.3%) and $49.19 with Cipro XR (resistance rate 1.0%).
In scenario 1b, the average total treatment cost was $60.14 with TMP-SMX (resistance rate 15.3%) and $50.55 with Cipro XR (resistance rate 1.0%).
In the break-even analysis (scenario 2), an average total treatment cost of $49.19 was achieved when the threshold resistance rate of TMP-SMX was 4.3% and the ciprofloxacin resistance rate was 1.0%.
In scenario 3 (excluding office visits and cost of urinalysis), the average cost per patient (with a resistance threshold of 4.3%) was $4.19 for both treatment options.
In scenario 4, the threshold rate of TMP-SMX resistance was 2.8% for an equal treatment cost of $54.87.
In the worst-case scenario (with a Cipro XR resistance rate of 10%), the TMP-SMX resistance threshold rate increased to 13.3% to reach an average treatment cost of $57.50 for both groups.
